Seeking Alpha

With its shares near their 52-week low thanks to weak earnings and fears of medical research...

With its shares near their 52-week low thanks to weak earnings and fears of medical research spending cuts, Thermo Fisher Scientific (TMO) has authorized a new $750M stock buyback plan, good for over 4% of outstanding shares at their current price. The lab equipment maker has only $25M left on an existing authorization.
Comments (1)
  • mdmrjsds
    , contributor
    Comments (502) | Send Message
     
    Interesting implications of this. What they are telling shareholders that the long term prospects of the company are poor, because management is focused on the short term. If they can't fund research that leads to increased earnings when earnings are weak, when will they and what does that suggest that management thinks are the future prospects of the company? I hope the board is making note of this, particularly the compensation and retention committees.
    11 Nov 2011, 09:39 AM Reply Like
DJIA (DIA) S&P 500 (SPY)